FDA — authorised 22 March 2013
- Application: NDA201688
- Marketing authorisation holder: VIATRIS
- Local brand name: TOBI PODHALER
- Indication: POWDER — INHALATION
- Status: approved
FDA authorised TOBI® PODHALER® on 22 March 2013
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 22 March 2013; FDA has authorised it.
VIATRIS holds the US marketing authorisation.